This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ariad's Leukemia Drug Toxic, Survey Says

CAMBRIDGE, Mass. ( TheStreet) -- The nettlesome issue of toxicity tied to Ariad Pharmaceutical's leukemia drug Iclusig was raised again Wednesday in a small survey of oncologists conducted by Favus Insitutional Research.

Ariad shares fell 4.1% on Wednesday to $16.76.


The more we learn about Iclusig, the less it appears to be a frontline CML drug. As the number of cases of liver toxicity, pancreatitis, abdominal pain, severe acute hypertension, heart attack, stroke, TIA, digital ischemia, and gastrointestinal perforation rise, investors' faith in Iclusig will fall, and so will the price of ARIA shares. Iclusig has a very small role to play in heavily pre-treated CML patients with the T315I mutation (extremely rare); as time goes on, that observation is becoming obvious. Don't be the last to know...

Favus surveyed 13 oncologists who have treated 77 patients with Iclusig since the FDA approval in December. Thirty-nine of the patients, or just over half, transferred from Ariad's pre-approval, expanded access program (EAP.) Another 10 patients (13%) have already discontinued Iclusig. The doctors surveyed told Favus that Iclusig is being used primarily in the small subgroup of CML patients with the T315I mutation, contradicting Ariad's claims that the drug is being more widely used.

BMO Capital Markets analyst Jim Birchenough came to Ariad's defense in a note criticial of Favus' methodology:


We would remind investors that patients enrolled in the Iclusig expanded access program (EAP) represent the sickest patient population, with a disproportionately high group of patients with blast phase (BP) or accelerated phase (AP) disease, only 40% of patients with chronic phase (CP) disease and at highest risk of imminent death, warranting EAP use of Iclusig ahead of approval. We also believe that the Iclusig EAP selected for patients with T315i mutation and is not representative of the labeled indication or expected broader commercial use. Indeed, expert feedback, and that from ARIA management over the last few days, suggests broad use of Iclusig across lines of therapy and independent of mutation status."

Iclusig and Pfizer's (PFE - Get Report) Bosulif are the most recently approved drugs to treat CML and compete against Novartis' (NVS - Get Report) Gleevec and Tasigna as well as Bristol-Myers Squibb's (BMY - Get Report) Sprycel.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARIA $7.04 -3.60%
BMY $71.14 -1.10%
NVS $76.07 -1.00%
PFE $33.71 2.80%
AAPL $95.18 1.60%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs